comunicacio

A receptor until now considered a death promoter in tumor cells could induce the growth of lung cancer

A study by IDIBELL and the University of Amsterdam published in the journal Cell Death and Disease shows that TRAIL protein receptors induce the expression of IL-8, a protein that promotes tumor development and angiogenesis in lung tumors.

A receptor until now considered a death promoter in tumor cells could induce the growth of lung cancer Read More »

Does everything cause cancer? Beliefs about cancer among anti-vaxxers and flat earthers: a call to combat misinformation

A team from IDIBELL and the Catalan Institute of Oncology has published the results of a survey that shows that anti-vaccine groups, flat earthers or defenders of the existence of reptilians recognize less the actual cancer causes, and therefore, identify false myths as carcinogens.

Does everything cause cancer? Beliefs about cancer among anti-vaxxers and flat earthers: a call to combat misinformation Read More »

Almost 90% of deaths and illnesses in Spain were due to non-infectious diseases such as heart disease, stroke, COPD, Alzheimer’s, and lung cancer

Based on the ‘Global Burden of Disease’ 2019, national researchers led by CIBER, and other Spanish and North American centers, including IDIBELL and ICO, draw a detailed picture of the health in Spain before the pandemic and offer a vision of the future trends.

Almost 90% of deaths and illnesses in Spain were due to non-infectious diseases such as heart disease, stroke, COPD, Alzheimer’s, and lung cancer Read More »

Researchers develop a model that predicts the COVID-19 clinical evolution at the hospital admission point

A joint project from the UPC, the UB, the HUB, and IDIBELL studied the probability of suffering severe pneumonia, needing ventilation, or even dying during hospital admission due to COVID-19. As a result of the statistical models created, based on data from more than 5,000 patients admitted to five hospitals in different pandemic waves, they developed a web application for the early identification of potentially high-risk COVID-19 patients and the prediction of the disease course.

Researchers develop a model that predicts the COVID-19 clinical evolution at the hospital admission point Read More »

hna Foundation collaborates in the development of a new drug against inflammatory bowel diseases

This support will help to develop and characterize a new immunomodulatory compound discovered by the IDIBELL group led by Dr. Josep Maria Aran.

hna Foundation collaborates in the development of a new drug against inflammatory bowel diseases Read More »

CAC, IDIBELL and the Bellvitge University Hospital culminate the study What do you bet? about the risks of video games and gambling

The didactic material presented a year ago has been reviewed after its application as a pilot test with 3rd and 4th ESO students at the Virolai School and the Bellvitge Institute. The study concludes that educational programs prevent addictions to video games and gambling.

CAC, IDIBELL and the Bellvitge University Hospital culminate the study What do you bet? about the risks of video games and gambling Read More »

Researchers identify an effective therapeutic strategy against a subtype of melanoma currently with no treatment

Researchers have observed that, in the absence of glucose, tumor cells become sensitive to treatment with sorafenib, a drug that was approved years ago for other indications.

Researchers identify an effective therapeutic strategy against a subtype of melanoma currently with no treatment Read More »

Symposium on Tobacco Control organized jointly with the World Health Organization

During the day, the Tobacco Control Scale was presented which describes the actions taken for tobacco control implemented in the 27 countries of the European Union plus 10 non-EU countries and which places the Spanish State in a situation very similar to that presented in the last edition in the year 2019

Symposium on Tobacco Control organized jointly with the World Health Organization Read More »

Scroll to Top